Market Leading Results from Phase 2 Clinical Trial: Multi-Target Therapeutics in Atopic Dermatitis and Epidermolysis Bullosa
Time: 12:00 pm
day: Day Two Translational Track AM
Details:
- Discover the innovative multi-target therapeutics with market-leading results in Atopic Dermatitis and Epidermolysis Bullosa
- Uncover the robust clinical evidence supporting multiple mechanisms of action, including anti-inflammatory, anti-itch, and antibacterial properties
- Dive into the comprehensive safety profile of AB101-a, a game-changer for Atopic Dermatitis
